徳島大学 教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University

徳島大学ウェブサイトへのリンク

著作: [福本 誠二]/Matsumoto Toshio/Recent advances in the management of osteoporosis./[F1000Research]

ヘルプを読む

「著作」(著作(著書,論文,レター,国際会議など))は,研究業績にかかる著作(著書,論文,レター,国際会議など)を登録するテーブルです. (この情報が属するテーブルの詳細な定義を見る)

  • 項目名の部分にマウスカーソルを置いて少し待つと,項目の簡単な説明がツールチップ表示されます.

この情報をEDB閲覧画面で開く

EID
334752
EOID
894670
Map
0
LastModified
2018年3月23日(金) 17:33:59
Operator
福本 誠二
Avail
TRUE
Censor
0
Owner
福本 誠二
Read
継承
Write
継承
Delete
継承
種別 必須 総説·解説
言語 必須 英語
招待 推奨
審査 推奨
カテゴリ 推奨
共著種別 推奨
学究種別 推奨
組織 推奨
著者 必須
  1. 福本 誠二([徳島大学.先端酵素学研究所.基幹研究部門])
    役割 任意
    貢献度 任意
    学籍番号 推奨
  2. (英) Matsumoto Toshio
    役割 任意
    貢献度 任意
    学籍番号 推奨
題名 必須

(英) Recent advances in the management of osteoporosis.

副題 任意
要約 任意

(英) There has been substantial progress in the management of patients with osteoporosis and the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are bisphosphonates and an anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody, denosumab. Although bisphosphonates and denosumab both inhibit bone resorption and prevent vertebral and non-vertebral fractures, their mechanisms of action are different. Whereas bisphosphonates' effects on bone mineral density and fracture peak around 3 to 5 years and become plateaued, those of denosumab are maintained for up to 10 years. There are differences in the modes of action of these two drugs. Bisphosphonates accumulate on the mineralized bone surface and are released by the acid environment under osteoclastic bone resorption, whereas denosumab is not accumulated on bone but directly binds RANKL and inhibits its binding to the receptor RANK. Thus, the reduction in denosumab concentration 4 to 6 months after injection may enable RANK to bind to RANKL, where it is highly expressed, such as in damaged bone regions. As anabolic agents, only teriparatide has been available for a long time, but abaloparatide, a synthetic analog of PTHrP(1-34), is currently under development. Because of the difference in the preferential binding conformations of PTH1 receptor between teriparatide and abaloparatide, the latter shows anabolic effects with fewer bone resorptive effects. Romosozumab, an anti-sclerostin antibody, inhibits the action of sclerostin, a canonical Wnt signal inhibitor secreted from osteocytes, and enhances canonical Wnt signaling. Romosozumab robustly increases vertebral and proximal femoral bone mineral density within 12 months and inhibits vertebral and clinical fractures in patients with osteoporosis by enhancing bone formation and inhibiting bone resorption. In this review, we summarize the recent advances in therapeutic agents for the treatment of osteoporosis and discuss future prospects with their use.

キーワード 推奨
発行所 推奨
誌名 必須 F1000Research(F1000 Research Ltd)
(eISSN: 2046-1402)
ISSN 任意 2046-1402
ISSN: 2046-1402 (eISSN: 2046-1402)
Title: F1000Research
Title(ISO): F1000Res
Publisher: F1000 Research Ltd.
 (NLM Catalog  (Scopus  (CrossRef (Scopus information is found. [need login])
必須 6
必須
必須 625 625
都市 任意
年月日 必須 2017年 5月 5日
URL 任意
DOI 任意 10.12688/f1000research.10682.1    (→Scopusで検索)
PMID 任意 28529724    (→Scopusで検索)
NAID 任意
WOS 任意
Scopus 任意
評価値 任意
被引用数 任意
指導教員 推奨
備考 任意
  1. (英) Article.ELocationID: 10.12688/f1000research.10682.1

  2. (英) Article.PublicationTypeList.PublicationType: Journal Article

  3. (英) Article.PublicationTypeList.PublicationType: Review

  4. (英) KeywordList.Keyword: abaloparatide

  5. (英) KeywordList.Keyword: bisphosphonates

  6. (英) KeywordList.Keyword: denosumab

  7. (英) KeywordList.Keyword: osteoporosis

  8. (英) KeywordList.Keyword: romosozumab

  9. (英) KeywordList.Keyword: teriparatide

  10. (英) CoiStatement: Competing interests: TM is a member of the advisory boards for Eli Lilly and Company and Amgen and is a consultant for Chugai, Daiichi-Sankyo, Astellas, and Teijin Pharma. SF declares that he has no competing interests.No competing interests were disclosed.Competing interests: Advisory Board member of Amgen, Merck, Lilly, Radius Health and consulting for Daiichi Sankyo.No competing interests were disclosed.